Luis López‐Gómez

457 total citations
16 papers, 334 citations indexed

About

Luis López‐Gómez is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Luis López‐Gómez has authored 16 papers receiving a total of 334 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Pathology and Forensic Medicine and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Luis López‐Gómez's work include Colorectal Cancer Treatments and Studies (9 papers), Cancer Treatment and Pharmacology (7 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). Luis López‐Gómez is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Cancer Treatment and Pharmacology (7 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). Luis López‐Gómez collaborates with scholars based in Spain, Colombia and Bangladesh. Luis López‐Gómez's co-authors include Jaime Feliú, P. Escudero, Manuel González-Barón, Alfonso Yubero, E. Casado, Javier de Castro, Antonieta Salud, Rafael López‐López, Ferrán Losa and António Galán de Mera and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and European Journal of Cancer.

In The Last Decade

Luis López‐Gómez

15 papers receiving 323 citations

Peers

Countries citing papers authored by Luis López‐Gómez

Since Specialization

Citations

This map shows the geographic impact of Luis López‐Gómez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luis López‐Gómez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luis López‐Gómez more than expected).

Fields of papers citing papers by Luis López‐Gómez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luis López‐Gómez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luis López‐Gómez. The network helps show where Luis López‐Gómez may publish in the future.

Co-authorship network of co-authors of Luis López‐Gómez

This figure shows the co-authorship network connecting the top 25 collaborators of Luis López‐Gómez. A scholar is included among the top collaborators of Luis López‐Gómez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luis López‐Gómez. Luis López‐Gómez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	A step-by-step guide to creating an academic surgery interest group: Review article 2021 ·Annals of Medicine and Surgery ·(unknown), (unknown), (unknown), (unknown), (unknown), Ivan David Lozada‐Martínez, Luis López‐Gómez, (unknown), (unknown)	11
2	Long‐term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90‐yttrium‐ibritumomab‐tiuxetan 2016 ·European Journal Of Haematology ·Marcio Andrade‐Campos, (unknown), (unknown), (unknown), (unknown), Luis López‐Gómez, (unknown), Pilar Giraldo	7
3	Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With 90Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience 2015 ·Clinical Lymphoma Myeloma & Leukemia ·Marcio Andrade‐Campos, (unknown), (unknown), (unknown), Luis López‐Gómez, (unknown), Pilar Giraldo	6
4	NEOHX study: Perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER-2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma—18 m DFS analysis. 2015 ·Journal of Clinical Oncology ·Fernando Rivera, Paula Jiménez‐Fonseca, Pilar Alfonso, Javier Gállego, María Luisa Limón, María Alsina, Luis López‐Gómez, (unknown), E. Falcó, José Luís Zamora Manzano, Encarnación González‐Flores, Enrique Aranda, (unknown), (unknown)	22
5	Long-term efficacy of 90Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life 2014 ·Annals of Hematology ·Marcio Andrade‐Campos, (unknown), (unknown), (unknown), Luis López‐Gómez, (unknown), Pilar Giraldo	9
6	NeoHx study: Perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma—R0 resection, pCR, and toxicity analysis. 2013 ·Journal of Clinical Oncology ·Fernando Rivera, (unknown), Pilar Alfonso, Carlos López, Javier Gállego, María Luisa Limón, María Alsina, Luis López‐Gómez, Maica Galán, E. Falcó, José Luís Zamora Manzano, Encarnación González‐Flores, Raquel Serrano, (unknown), (unknown)	13
7	Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer 2010 ·Cancer Chemotherapy and Pharmacology ·Jaime Feliú, Pablo Borrega, Ana León, Luis López‐Gómez, (unknown), Javier de Castro, Cristóbal Belda-Iniesta, Jorge Barriuso, Virginia Martínez, M. González‐Barón	26
8	XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer 2006 ·British Journal of Cancer ·Jaime Feliú, Antonieta Salud, P. Escudero, Luis López‐Gómez, Marc Bolaños, António Galán de Mera, (unknown), Alfonso Yubero, Ferrán Losa, Javier de Castro, (unknown), E. Casado, Manuel González-Barón	80
9	Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer 2005 ·British Journal of Cancer ·(unknown), Jaime Feliú, (unknown), Antonieta Salud, J. R. Mel, (unknown), André Pèlegrin, Luis López‐Gómez, María C. Ruiz, Encarnación González‐Flores, (unknown), (unknown), Javier de Castro, Manuel González-Barón	31
10	XELOX (capecitabine and oxaliplatin) as 1^st line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC) 2005 ·Journal of Clinical Oncology ·Antonieta Salud, P. Escudero, Jaime Feliú, Luis López‐Gómez, (unknown), António Galán de Mera, Alfonso Yubero, (unknown), Ferrán Losa, Manuel González Barón	7
11	Capecitabine As First-Line Treatment for Patients Older Than 70 Years With Metastatic Colorectal Cancer: An Oncopaz Cooperative Group Study 2005 ·Journal of Clinical Oncology ·Jaime Feliú, P. Escudero, (unknown), (unknown), (unknown), Alfonso Yubero, (unknown), Rafael López‐López, Luis López‐Gómez, E. Casado, (unknown), Manuel González-Barón	94
12	Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study 2004 ·British Journal of Cancer ·Jaime Feliú, Antonieta Salud, P. Escudero, Luis López‐Gómez, Carles Pericay, (unknown), (unknown), Julián Rodríguez‐García, (unknown), (unknown), José Javier Sánchez, Manuel González Barón	20
13	XELOX (capecitabine and oxaliplatin) as 1st line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC) 2004 ·Journal of Clinical Oncology ·Luis López‐Gómez, (unknown), Alfonso Yubero, Joel Feliu i Samuel-Lajeunesse, Antonieta Salud, António Galán de Mera, Marc Bolaños, (unknown), Ferrán Losa, Manuel González-Barón	0
14	XELOX (capecitabine and oxaliplatin) as 1st line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC) 2004 ·Journal of Clinical Oncology ·Luis López‐Gómez, (unknown), Alfonso Yubero, Joel Feliu i Samuel-Lajeunesse, Antonieta Salud, António Galán de Mera, Marc Bolaños, (unknown), Ferrán Losa, Manuel González-Barón	2
15	263 A study of capecitabine in elderly patients as first line treatment in advanced or metastatic colorectal cancer 2003 ·European Journal of Cancer Supplements ·Jaime Feliú, P. Escudero, Ferrán Losa, Marc Bolaños, (unknown), Alfonso Yubero, (unknown), Rocío López, Luis López‐Gómez, M. González‐Barón	4
16	Phase II trial of gemcitabine-UFT-leucovorin (ILV) in advanced carcinoma of the pancreas: preliminary results 1999 ·European Journal of Cancer ·Joel Feliu i Samuel-Lajeunesse, (unknown), (unknown), Manuel Constenla, Javier Espinosa, (unknown), Luis López‐Gómez, Yolanda Fernández, Javier de Castro, Manuel González Barón	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact